Arvin  Yang net worth and biography

Arvin Yang Biography and Net Worth

Arvin joined Mersana in November 2020, bringing deep experience in leading early-stage trials and late-stage global registrational trials. Prior to joining Mersana, Arvin spent over a decade at Bristol Myers Squibb in various roles with increasing responsibility for the clinical development of hematology and oncology including immuno-oncology therapies. Most recently, he was Vice President and Head of Clinical Hematology. Before that, he was Vice President and Development Lead for Melanoma and GU cancers, and played a critical role in the global approval of nivolumab and nivolumab plus ipilimumab combinations in a number of indications. Earlier, he was responsible for the nivolumab and ipilimumab life-cycle clinical development plans including those in gynecological cancers. Finally, he has held leadership roles overseeing a pipeline of early clinical programs as well as roles in medical affairs.  

Dr. Yang received his M.D. and Ph.D. from Rutgers Robert Wood Johnson Medical School and completed training in internal medicine at Beth Israel Deaconess, Harvard Medical School and in oncology at Memorial Sloan-Kettering Cancer Center.

What is Arvin Yang's net worth?

The estimated net worth of Arvin Yang is at least $115,886.96 as of January 17th, 2023. Dr. Yang owns 30,821 shares of Mersana Therapeutics stock worth more than $115,887 as of April 16th. This net worth estimate does not reflect any other investments that Dr. Yang may own. Learn More about Arvin Yang's net worth.

How do I contact Arvin Yang?

The corporate mailing address for Dr. Yang and other Mersana Therapeutics executives is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. Mersana Therapeutics can also be reached via phone at (617) 498-0020 and via email at [email protected]. Learn More on Arvin Yang's contact information.

Has Arvin Yang been buying or selling shares of Mersana Therapeutics?

Arvin Yang has not been actively trading shares of Mersana Therapeutics over the course of the past ninety days. Most recently, Arvin Yang sold 2,209 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $5.74, for a transaction totalling $12,679.66. Following the completion of the sale, the senior vice president now directly owns 30,821 shares of the company's stock, valued at $176,912.54. Learn More on Arvin Yang's trading history.

Who are Mersana Therapeutics' active insiders?

Mersana Therapeutics' insider roster includes Lawrence Alleva (Director), Andrew Hack (Director), Timothy Lowinger (Insider), Ashish Mandelia (VP), Anna Protopapas (CEO), and Arvin Yang (Insider). Learn More on Mersana Therapeutics' active insiders.

Are insiders buying or selling shares of Mersana Therapeutics?

During the last twelve months, insiders at the sold shares 7 times. They sold a total of 54,872 shares worth more than $147,416.84. The most recent insider tranaction occured on January, 16th when Director Anna Protopapas sold 29,399 shares worth more than $79,671.29. Insiders at Mersana Therapeutics own 12.5% of the company. Learn More about insider trades at Mersana Therapeutics.

Information on this page was last updated on 1/16/2024.

Arvin Yang Insider Trading History at Mersana Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2023Sell2,209$5.74$12,679.6630,821View SEC Filing Icon  
12/1/2021Sell5,527$6.81$37,638.87View SEC Filing Icon  
See Full Table

Arvin Yang Buying and Selling Activity at Mersana Therapeutics

This chart shows Arvin Yang's buying and selling at Mersana Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mersana Therapeutics Company Overview

Mersana Therapeutics logo
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.76
Low: $3.71
High: $3.81

50 Day Range

MA: $4.50
Low: $3.59
High: $5.94

2 Week Range

Now: $3.76
Low: $0.80
High: $9.62


682,987 shs

Average Volume

2,213,186 shs

Market Capitalization

$456.09 million

P/E Ratio


Dividend Yield